Michael Soles
Internal Medicine · Los Angeles, CANPI 1073604898
Payments from drug & device makers
Across 365 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$3K
- Gilead$1K
- Merck$996
- Johnson & Johnson$744
- AbbVie$343
- Amgen$51
- plus $40 from 2 others
What the payments were for
- Food & beverage$6,50799%
- Education$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 137 | $3,070 |
| Gilead | 99 | $1,302 |
| Merck | 57 | $996 |
| Johnson & Johnson(2 entities) | 44 | $744 |
| AbbVie | 23 | $343 |
| Amgen | 3 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| GSK | 1 | $20 |
How this compares
$6,547 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 109 | $453,029 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 32 | $184,440 |
| DescovyEmtricitabine/Tenofov Alafenam | 40 | $87,622 |
| DovatoDolutegravir Sodium/Lamivudine | 29 | $86,615 |
| TivicayDolutegravir Sodium | 25 | $56,167 |
| IsentressRaltegravir Potassium | 24 | $46,099 |
| PrezcobixDarunavir/Cobicistat | 12 | $28,012 |
| PifeltroDoravirine | 13 | $23,001 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $1,792 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $508 |
| Atorvastatin Calcium | 106 | $486 |
| Rosuvastatin Calcium | 34 | $308 |
| Omega-3 Acid Ethyl Esters | 24 | $297 |
| Ibuprofen | 38 | $266 |
| Chlorthalidone | 33 | $237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $1,302 | $540,650149 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $3,070 | $142,78254 claims |
| MerckIsentress, Pifeltro | $996 | $69,10037 claims |
| Johnson & JohnsonPrezcobix | $744 | $28,01212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William TownerLos Angeles$27.4M
- Herbert EradatLos Angeles$11.6M
- Deborah WongLos Angeles$10.7M
- Robin KelleyLos Angeles$5.8M
- David GuzmanLos Angeles$4.3M
- Siwen Hu-LieskovanLos Angeles$2.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- Rahul AggarwalSan Francisco$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.